Amy Cutrell

3.0k citations

18 papers · 1.1k indexed · h-index 13

Impact in

Virology top 1%
- HIV Research and Treatment
Infectious Diseases top 2%
- HIV/AIDS drug development and treatment
- HIV/AIDS Research and Interventions

Papers in ⓘ

Infectious Diseases 17
- HIV/AIDS drug development and treatment 16
- HIV/AIDS Research and Interventions 13
Virology 12
- HIV Research and Treatment 12

Co-authors: Helen Steel (3 shared papers)Seth Hetherington (3 shared papers)Gill Pearce (1 shared paper)Odin Naderer (1 shared paper)Mounir Ait‐Khaled (3 shared papers)Christine Katlama (4 shared papers)William Spreen (6 shared papers)Gillian Pearce (2 shared papers)
Journals: AIDS (4 papers)HIV Medicine (2 papers)Clinical Therapeutics (2 papers)Liver International (1 paper)JAIDS Journal of Acquired Immune Deficiency Syndromes (1 paper)
Partner nations: United States United Kingdom Germany

In The Last Decade

Amy Cutrell

18 papers receiving 1.0k citations

Peers

Countries citing papers authored by Amy Cutrell

Since Specialization

Citations

This map shows the geographic impact of Amy Cutrell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amy Cutrell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amy Cutrell more than expected).

Fields of papers citing papers by Amy Cutrell

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amy Cutrell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amy Cutrell. The network helps show where Amy Cutrell may publish in the future.

Co-authors

The 25 scholars most cited alongside Amy Cutrell, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Amy Cutrell Line = papers co-authored together Amy Cutrell links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work
1	Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir Clinical Therapeutics ·Seth Hetherington, Sue McGuirk, Gwendolyn Powell, Amy Cutrell, Odin Naderer, Bill Spreen, Steve Lafon, Gill Pearce, Helen Steel	2001	299
2	Risk of Myocardial Infarction and Abacavir Therapy: No Increased Risk Across 52 GlaxoSmithKline-Sponsored Clinical Trials in Adult Subjects JAIDS Journal of Acquired Immune Deficiency Syndromes ·Cindy Brothers, Jaime E. Hernández, Amy Cutrell, Lloyd Curtis, Mounir Ait‐Khaled, Steve J. Bowlin, Sara Hughes, Jane Yeo, Didier Lapierre	2009	133
3	HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy AIDS ·Veronica Miller, Mounir Ait‐Khaled, Christopher Stone, Philip Griffin, D. Mesogiti, Amy Cutrell, Richard Harrigan, Schlomo Staszewski, Christine Katlama, Gillian Pearce, Margaret Tisdale	2000	107
4	Risk factor analysis of hypersensitivity reactions to abacavir Clinical Therapeutics ·William T. Symonds, Amy Cutrell, Mark T Edwards, Helen Steel, Bill Spreen, Gwendolyn Powell, Sue McGuirk, Seth Hetherington	2002	90
5	Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study The Lancet HIV ·Chloe Orkin, Enrique Bernal, Darrell H. S. Tan, Harold Katner, Hans‐Jürgen Stellbrink, Elena Belonosova, Rebecca DeMoor, Sandy Griffith, Shanker Thiagarajah, Rodica Van Solingen‐Ristea, Susan L. Ford, Herta Crauwels, Parul Patel, Amy Cutrell, Kimberly Y. Smith, Kati Vandermeulen, Eileen Birmingham, Marty St. Clair, William Spreen, Ronald D’Amico	2021	88
6	A dose-ranging study to evaluate the safety and efficacy of abacavir alone or in combination with zidovudine and lamivudine in antiretroviral treatment-naive subjects AIDS ·Schlomo Staszewski, Christine Katlama, Thomas Harrer, Patrice Massip, Patrick Yéni, Amy Cutrell, Stephanie M. Tortell, Richard Harrigan, Helen Steel, Randall Lanier, Gillian Pearce	1998	74
7	Cellular restoration in HIV infected persons treated with abacavir and a protease inhibitor: age inversely predicts naive CD4 cell count increase AIDS ·Michael M. Lederman, Ray A. McKinnis, Dennis Kelleher, Amy Cutrell, John W. Mellors, Mike Neisler, Elizabeth Cooney, David W. Haas, Richard Haubrich, James Stanford, James Horton, Alan Landay, William Spreen	2000	69
8	The role of abacavir (ABC, 1592) in antiretroviral therapy-experienced patients: results from a randomized, double-blind, trial AIDS ·Christine Katlama, Bonaventura Clotet, Andreas Plettenberg, Josef Jost, Keikawus Arastéh, Enos Bernasconi, Vincent Jeantils, Amy Cutrell, Christopher Stone, Mounir Ait‐Khaled, Scot E. Purdon	2000	49
9	Compassionate use of long‐acting cabotegravir plus rilpivirine for people living with HIV‐1 in need of parenteral antiretroviral therapy HIV Medicine ·Ronald D’Amico, Santiago Cenoz Gomis, Riya Moodley, Rodica Van Solingen‐Ristea, Bryan Baugh, Erika Van Landuyt, Veerle Van Eygen, Sherene Min, Amy Cutrell, Caroline Foster, Daniella Chilton, Sabine Allard, Annemiek de Ruiter	2022	35
10	Population pharmacokinetics of cabotegravir following administration of oral tablet and long‐acting intramuscular injection in adult HIV‐1‐infected and uninfected subjects British Journal of Clinical Pharmacology ·Kelong Han, Mark Baker, Mark Lovern, Prokash Paul, Yuan Xiong, Parul Patel, Katy Moore, Ciara Seal, Amy Cutrell, Ronald D’Amico, Paul Benn, Raphael J. Landovitz, Mark A. Marzinke, William Spreen, Susan L. Ford	2022	32
11	A Randomized, Double-Blind Study of Triple Nucleoside Therapy of Abacavir, Lamivudine, and Zidovudine Versus Lamivudine and Zidovudine in Previously Treated Human Immunodeficiency Virus Type 1-Infected Children PEDIATRICS ·Xavier Sáez‐Llorens, Robert P. Nelson, Patricia Emmanuel, Andrew Wiznia, Charles D. Mitchell, Joseph A. Church, John W. Sleasman, Russell Van Dyke, Carol Richardson, Amy Cutrell, William Spreen, Seth Hetherington, (unknown)	2001	29
12	Antiretroviral Activity and Safety of Abacavir in Combination with Selected HIV-1 Protease Inhibitors in Therapy-Naive HIV-1-Infected Adults Antiviral Therapy ·Deborah K. McMahon, Michael M. Lederman, David W. Haas, Richard Haubrich, James Stanford, Elizabeth Cooney, James Horton, Dennis Kelleher, Lisa Ross, Amy Cutrell, Diana Lee, William Spreen, John W. Mellors	2001	17
13	HIV prevention trial design in an era of effective pre-exposure prophylaxis HIV Clinical Trials ·Amy Cutrell, Deborah Donnell, David Dunn, David V. Glidden, Anneke Grobler, Brett Hanscom, Britt Stancil, R. Daniel Meyer, Ronnie Wang, Robert L. Cuffe	2017	16
14	Intensification of stable background therapy with abacavir in antiretroviral therapy experienced patients: 48‐week data from a randomized, double‐blind trial HIV Medicine ·Christine Katlama, B Clotet, Andreas Plettenberg, Josef Jost, Keikawus Arastéh, Enos Bernasconi, Vincent Jeantils, Amy Cutrell, Caroline J. Stone, Scot E. Purdon, (unknown)	2001	11
15	Facilitating Next‐Generation Pre‐Exposure Prophylaxis Clinical Trials Using HIV Recent Infection Assays: A Consensus Statement from the Forum HIV Prevention Trial Design Project Clinical Pharmacology & Therapeutics ·Neil Parkin, Fei Gao, Eduard Grebe, Amy Cutrell, Moupali Das, Deborah Donnell, Ann Duerr, David V. Glidden, James P. Hughes, Jeffrey S. Murray, Michael Robertson, J. Zinserling, Joseph Lau, Veronica Miller	2022	10
16	A Double‐blind, randomized, placebo‐controlled study to assess the safety, antiviral activity and pharmacokinetics of GSK2336805 when given as monotherapy and in combination with peginterferon alfa‐2a and ribavirin in hepatitis C virus genotype 1‐infected treatment‐naive subjects Liver International ·Stephen D. Gardner, Amy Cutrell, Cindy Elko‐Simms, Kimberly K. Adkison, Robert Hamatake, Jill Walker, M. Rodríguez‐Torres, Zhi Hong	2013	7
17	884. Patient Adherence to Long-Acting Injectable Cabotegravir + Rilpivirine Through 48 Weeks of Maintenance Therapy in the Phase 3 ATLAS and FLAIR Studies Open Forum Infectious Diseases ·Paula Teichner, Amy Cutrell, Ronald D’Amico, David Dorey, Sandy Griffith, Conn Harrington, Jenny Huang, Krischan J Hudson, David M. Margolis, Joseph Mrus, Joseph W. Polli, William Spreen, Peter Williams, Rodica Van Solingen‐Ristea, Mark S. Shaefer	2019	4
18	Changes over time in creatinine clearance and comparison of emergent adverse events for HIV-positive adults receiving standard doses (300 mg/day) of lamivudine-containing antiretroviral therapy with baseline creatinine clearance of 30–49 vs ≥50 mL/min PLoS ONE ·Lisa Ross, A. Sarah Walker, Yu Lou, Allan R. Tenorio, Diana M. Gibb, Julia Double, Charles F. Gilks, Cynthia McCoig, Paula Munderi, Godfrey Musoro, Cissy Kityo, Heiner Grosskurth, James Hakim, Peter Mugyenyi, Amy Cutrell, Teodora Perger, Mark S. Shaefer	2019	2

About Amy Cutrell

Amy Cutrell is a scholar working on Infectious Diseases, Virology, Emergency Medicine, Pharmacology and Epidemiology, having authored 18 papers that have together received 1.1k indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (16 papers), HIV/AIDS Research and Interventions (13 papers), HIV Research and Treatment (12 papers), HIV-related health complications and treatments (3 papers), Hepatitis C virus research (2 papers), Pneumocystis jirovecii pneumonia detection and treatment (2 papers), Drug-Induced Adverse Reactions (2 papers) and Systemic Lupus Erythematosus Research (1 paper). The work is most often cited by research in Virology (581 citations), Infectious Diseases (752 citations), Emergency Medicine (223 citations), Pharmacology (253 citations) and Epidemiology (227 citations). Amy Cutrell has collaborated with scholars based in United States, United Kingdom and Germany. Frequent co-authors include Helen Steel, Seth Hetherington, Gill Pearce, Odin Naderer, Mounir Ait‐Khaled, Christine Katlama, William Spreen, Gillian Pearce, Jane Yeo and Cindy Brothers. Their work appears in journals such as AIDS, HIV Medicine, Clinical Therapeutics, Liver International and JAIDS Journal of Acquired Immune Deficiency Syndromes.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact